000			03949nam a2200421 i 4500
999			_c374587 _d374587
001			374587
003			ES-MaUEC
005			20230703103433.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			160208s2016 sz a s |||| 0|eng d
020			_a9783319264646
024	7		_a10.1007/978-3-319-26464-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC _dES-MaUEC
050		4	_aR853.S7 _b2016 EB
100	1		_aKatz, Martin M. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9688647
245	1	0	_aClinical Trials of Antidepressants : _bHow Changing the Model Can Uncover New, More Effective Molecules _cby Martin M. Katz
250			_aFirst edition 2016
264		1	_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XV, 66 páginas) _bilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
490	0		_aSpringerBriefs in Psychology _x2192-8371
505	0		_aIntroduction -- Why Now the Need for a New Clinical Trial Model for Antidepressants? -- Reconceptualizing Depression and the Componential-Specific Model of Clinical Trials -- Aims and Basic requirements of Clinical Trials: Conventional and Component-Specific Models -- Methods for Measuring the Components and Profile of Drug Actions: The Multivantaged Approach -- The Component-Specific Model Applied in a Clinical Trial: An Example -- Comparing the Component-Specific Model Directly with the Established Diagnosis-Specific Trial -- Prediction and Shortening the Clinical Trial: Further Advantages of the Component-Specific Model -- The Video Clinical Trial and the VIBES Method -- Conclusions.
520			_aThis brief guide takes current clinical trial protocols to task and replaces them with a contemporary framework for improving next-generation antidepressants and their underlying science. Innovative models are based on a nuanced, neurologically-informed understanding of drug mechanisms and the component cognitive, mood, and behavioral aspects of depression. The book reconceptualizes not only the clinical trial process but the clinical concept of depression itself as essential to bringing pharmaceutical research and development up to date, boosting efficiency and effectiveness, finding new molecules, and reducing waste. Case studies and a review of salient depression scales illustrate the potential benefits of such wide-scale change. Included in the coverage: Why now the need for a new clinical trials model for antidepressants? Aims and basic requirements of clinical trials: conventional and component-specific models. Methods for measuring the components and the profile of drug actions: the multivantaged approach. Achieving the ideal clinical trial: an example of the merged componential and established models. Prediction and shortening the clinical trial. The video clinical trial. Clinical Trials of Antidepressants will interest a varied audience, including clinical investigators, academic and pharmaceutical company scientists, clinical trial organizations, psychiatrists, outpatient physicians, psychotherapists, clinical psychologists, psychology graduate students, medical students, and government agencies such as the FDA.
988			_aSpringer_Psychology_2016
650		7	_2embne _9144524 _aEnsayos clínicos
650		7	_2embne _9138046 _aPsicología
776	0	8	_iPrinted edition: _z9783319264639
776	0	8	_iPrinted edition: _z9783319264653
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-26464-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b05/2022 _dz _ek _zSI